Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines

Clint Mitchell, Margaret A. Park, Guo Zhang, Song Iy Han, Hisashi Harada, Richard A. Franklin, Adly Yacoub, Pin-Lan Li, Philip B. Hylemon, Steven Grant and Paul Dent
Clint Mitchell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret A. Park
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guo Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Song Iy Han
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisashi Harada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Franklin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adly Yacoub
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pin-Lan Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip B. Hylemon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Grant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Dent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-06-0532 Published February 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2007 to March 2021

AbstractFull-text HTMLPDF
Total163624381136

Cited By

Article Information

Volume 6, Issue 2, pp. 618-632

DOI 
https://doi.org/10.1158/1535-7163.MCT-06-0532
PubMed 
17308059

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • December 6, 2006
  • August 28, 2006
  • November 30, 2006
  • Published first February 16, 2007.

Copyright & Usage 
American Association for Cancer Research

Author Information

  1. Clint Mitchell1,
  2. Margaret A. Park1,
  3. Guo Zhang15,
  4. Song Iy Han1,
  5. Hisashi Harada2,
  6. Richard A. Franklin6,
  7. Adly Yacoub1,
  8. Pin-Lan Li5,
  9. Philip B. Hylemon4,
  10. Steven Grant12 and
  11. Paul Dent13
  1. Departments of 1Biochemistry, 2Medicine, 3Radiation Oncology, 4Microbiology and Immunology, and 5Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia and 6Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, North Carolina
  1. Requests for reprints: Paul Dent, Department of Biochemistry, Massey Cancer Center, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035. Phone: 804-628-0861; Fax: 804-827-1309. E-mail: pdent{at}vcu.edu
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 6 (2)
February 2007
Volume 6, Issue 2
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines
Clint Mitchell, Margaret A. Park, Guo Zhang, Song Iy Han, Hisashi Harada, Richard A. Franklin, Adly Yacoub, Pin-Lan Li, Philip B. Hylemon, Steven Grant and Paul Dent
Mol Cancer Ther February 1 2007 (6) (2) 618-632; DOI: 10.1158/1535-7163.MCT-06-0532

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines
Clint Mitchell, Margaret A. Park, Guo Zhang, Song Iy Han, Hisashi Harada, Richard A. Franklin, Adly Yacoub, Pin-Lan Li, Philip B. Hylemon, Steven Grant and Paul Dent
Mol Cancer Ther February 1 2007 (6) (2) 618-632; DOI: 10.1158/1535-7163.MCT-06-0532
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
  • Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
  • Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement